MUC4 Mucin Interacts with and Stabilizes the HER2 Oncoprotein in Human Pancreatic Cancer Cells

Overview

Journal Cancer Res

Specialty Oncology

Date 2008 Apr 3

PMID 18381409

Citations 103

Authors

Pallavi Chaturvedi

Ajay P Singh

Subhankar Chakraborty

Subhash C Chauhan

Sangeeta Bafna

Jane L Meza

Pankaj K Singh

Michael A Hollingsworth

Parmender P Mehta

Surinder K Batra

Affiliations

Soon will be listed here.

Abstract

MUC4, a high-molecular weight transmembrane glycoprotein, is overexpressed in pancreatic cancer and is implicated in its pathogenesis. It is a heterodimeric protein containing a large extracellular, heavily glycosylated subunit, MUC4alpha, and a transmembrane growth factor-like subunit, MUC4beta. In the present study, we have shown the interaction of human MUC4 with the receptor tyrosine kinase HER2 in pancreatic adenocarcinoma cells by reciprocal coimmunoprecipitation and cocapping studies. MUC4 colocalized with HER2 at the cell surface and in the cytoplasm. Silencing of MUC4 by transient or stable expression of MUC4-targeted short-interfering RNA led to the down-regulation of HER2 with a concomitant decrease in its phosphorylated form (pY(1248)-HER2). Further analyses revealed that the MUC4-knockdown-mediated decrease in HER2 expression occurred due to the drop in the stability of the receptor. In MUC4-knockdown pancreatic cancer cells, we also observed a reduced phosphorylation of the focal adhesion kinase and p42/44 mitogen-activated protein kinase, which are downstream effector proteins in HER2 signaling. Our findings add a new dimension to MUC4 function as a modulator of cell signaling and provide mechanistic evidence for its role in pancreatic cancer progression.

Citing Articles

Molecular genetic analysis of colorectal carcinoma with an aggressive extraintestinal immunohistochemical phenotype.

Hrudka J, Kalinova M, Fiserova H, Jelinkova K, Nikov A, Waldauf P Sci Rep. 2024; 14(1):22241.

PMID: 39333321 PMC: 11437151. DOI: 10.1038/s41598-024-72687-3.

Surface plasmon resonance microscopy identifies glycan heterogeneity in pancreatic cancer cells that influences mucin-4 binding interactions.

Aguilar Diaz de Leon J, Thirumurty M, Ly N PLoS One. 2024; 19(5):e0304154.

PMID: 38776309 PMC: 11111020. DOI: 10.1371/journal.pone.0304154.

Unraveling the role of C1GALT1 in abnormal glycosylation and colorectal cancer progression.

Tian H, Yu J, Chu X, Guan Q, Liu J, Liu Y Front Oncol. 2024; 14:1389713.

PMID: 38699634 PMC: 11063370. DOI: 10.3389/fonc.2024.1389713.

Relationship Between MUC4 Variants and Metastatic Recurrence in Colorectal Cancer.

Liu J, Xing R, Shao J, Jiao S Int J Gen Med. 2023; 16:5077-5087.

PMID: 37942474 PMC: 10629456. DOI: 10.2147/IJGM.S437957.

Mucin 4 Confers Gemcitabine Resistance and an Unfavorable Prognosis in Patients with Cholangiocarcinoma via AKT Activation.

Pan Y, Wu C, Jung S, Huang S, Lin S, Chou W Int J Biol Sci. 2023; 19(9):2772-2786.

PMID: 37324940 PMC: 10266071. DOI: 10.7150/ijbs.79126.

References

Seton-Rogers S, Lu Y, Hines L, Koundinya M, LaBaer J, Muthuswamy S . Cooperation of the ErbB2 receptor and transforming growth factor beta in induction of migration and invasion in mammary epithelial cells. Proc Natl Acad Sci U S A. 2004; 101(5):1257-62. PMC: 337040. DOI: 10.1073/pnas.0308090100. View

Singh P, Hollingsworth M . Cell surface-associated mucins in signal transduction. Trends Cell Biol. 2006; 16(9):467-76. DOI: 10.1016/j.tcb.2006.07.006. View

Moniaux N, Varshney G, Chauhan S, Copin M, Jain M, Wittel U . Generation and characterization of anti-MUC4 monoclonal antibodies reactive with normal and cancer cells in humans. J Histochem Cytochem. 2004; 52(2):253-61. DOI: 10.1177/002215540405200213. View

Moasser M . The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene. 2007; 26(45):6469-87. PMC: 3021475. DOI: 10.1038/sj.onc.1210477. View

Amundadottir L, Leder P . Signal transduction pathways activated and required for mammary carcinogenesis in response to specific oncogenes. Oncogene. 1998; 16(6):737-46. DOI: 10.1038/sj.onc.1201829. View

Singh A, Chaturvedi P, Batra S . Emerging roles of MUC4 in cancer: a novel target for diagnosis and therapy. Cancer Res. 2007; 67(2):433-6. DOI: 10.1158/0008-5472.CAN-06-3114. View

Chaturvedi P, Singh A, Moniaux N, Senapati S, Chakraborty S, Meza J . MUC4 mucin potentiates pancreatic tumor cell proliferation, survival, and invasive properties and interferes with its interaction to extracellular matrix proteins. Mol Cancer Res. 2007; 5(4):309-20. DOI: 10.1158/1541-7786.MCR-06-0353. View

Pochampalli M, el Bejjani R, Schroeder J . MUC1 is a novel regulator of ErbB1 receptor trafficking. Oncogene. 2006; 26(12):1693-701. DOI: 10.1038/sj.onc.1209976. View

Timms J, White S, OHare M, Waterfield M . Effects of ErbB-2 overexpression on mitogenic signalling and cell cycle progression in human breast luminal epithelial cells. Oncogene. 2002; 21(43):6573-86. DOI: 10.1038/sj.onc.1205847. View

10.

Ren J, Raina D, Chen W, Li G, Huang L, Kufe D . MUC1 oncoprotein functions in activation of fibroblast growth factor receptor signaling. Mol Cancer Res. 2006; 4(11):873-83. PMC: 3322466. DOI: 10.1158/1541-7786.MCR-06-0204. View

11.

Jepson S, Komatsu M, Haq B, Arango M, Huang D, Carraway C . Muc4/sialomucin complex, the intramembrane ErbB2 ligand, induces specific phosphorylation of ErbB2 and enhances expression of p27(kip), but does not activate mitogen-activated kinase or protein kinaseB/Akt pathways. Oncogene. 2002; 21(49):7524-32. DOI: 10.1038/sj.onc.1205970. View

12.

Holbro T, Hynes N . ErbB receptors: directing key signaling networks throughout life. Annu Rev Pharmacol Toxicol. 2004; 44:195-217. DOI: 10.1146/annurev.pharmtox.44.101802.121440. View

13.

Ilic D, Furuta Y, Kanazawa S, Takeda N, Sobue K, Nakatsuji N . Reduced cell motility and enhanced focal adhesion contact formation in cells from FAK-deficient mice. Nature. 1995; 377(6549):539-44. DOI: 10.1038/377539a0. View

14.

Hynes N, Lane H . ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005; 5(5):341-54. DOI: 10.1038/nrc1609. View

15.

Frisch S, Vuori K, Ruoslahti E . Control of adhesion-dependent cell survival by focal adhesion kinase. J Cell Biol. 1996; 134(3):793-9. PMC: 2120934. DOI: 10.1083/jcb.134.3.793. View

16.

Singh A, Moniaux N, Chauhan S, Meza J, Batra S . Inhibition of MUC4 expression suppresses pancreatic tumor cell growth and metastasis. Cancer Res. 2004; 64(2):622-30. DOI: 10.1158/0008-5472.can-03-2636. View

17.

Carraway 3rd K, Rossi E, Komatsu M, Huang D, Guy P, Carvajal M . An intramembrane modulator of the ErbB2 receptor tyrosine kinase that potentiates neuregulin signaling. J Biol Chem. 1999; 274(9):5263-6. DOI: 10.1074/jbc.274.9.5263. View

18.

Ramasamy S, Duraisamy S, Barbashov S, Kawano T, Kharbanda S, Kufe D . The MUC1 and galectin-3 oncoproteins function in a microRNA-dependent regulatory loop. Mol Cell. 2007; 27(6):992-1004. PMC: 4217170. DOI: 10.1016/j.molcel.2007.07.031. View

19.

Warren C, Landgraf R . Signaling through ERBB receptors: multiple layers of diversity and control. Cell Signal. 2006; 18(7):923-33. DOI: 10.1016/j.cellsig.2005.12.007. View

20.

PATERSON H, Marshall C, Yarden Y . A single autophosphorylation site confers oncogenicity to the Neu/ErbB-2 receptor and enables coupling to the MAP kinase pathway. EMBO J. 1994; 13(14):3302-11. PMC: 395227. DOI: 10.1002/j.1460-2075.1994.tb06632.x. View